Decipher Labs Closes Trading Window April 1 for FY26 Results

Decipher Labs Limited will temporarily suspend trading of its securities starting April 1, 2026. This blackout period will last until 48 hours after the company announces its financial results for the fiscal year ending March 31, 2026.

This aligns with SEBI's insider trading rules, aimed at preventing misuse of non-public information.

Trading Window Closure Announced

Decipher Labs has informed that its trading window will be closed for designated employees, their relatives, and connected individuals. This closure is required by SEBI's Prohibition of Insider Trading Regulations.

Understanding Trading Window Closures

These closures are a standard regulatory step for public companies. They prevent insider trading by ensuring no one trades on material non-public information, like upcoming financial results, before it's released to the public.

Background: SEBI Appeal and Past Penalties

The company and its leadership have a notable regulatory past. In August 2025, SEBI fined Decipher Labs, promoter Janakiram Ajjarapu, and director Sushant Mohan Lal, citing misleading announcements and enabling insider trading from late 2021 to early 2022. The company and its directors have appealed this SEBI order at the Securities Appellate Tribunal (SAT). SAT has temporarily halted the trading ban and penalties, provided a 50% deposit is made, while the appeal proceeds.

While past issues are relevant, this current trading window closure is a routine compliance action, common among pharmaceutical companies.

Impact on Insiders

Employees covered by the closure, along with their immediate family and associates, cannot trade Decipher Labs shares. This ban lasts until the official financial results are released and a 48-hour period following that announcement has passed. This safeguards market integrity by preventing trades based on unequal information.

Ongoing Regulatory Risk

Although this is a standard procedure, the company's appeal against the SEBI order on insider trading and misleading statements remains a significant background risk. Any outcomes from the SAT proceedings could impact investor confidence and Decipher Labs' regulatory standing.

Industry Standard Practice

Companies in the pharmaceutical sector, like Glenmark Pharmaceuticals, Hikal, and Zenith Healthcare, follow similar trading window closure practices for financial reporting. This is a standard procedure mandated by SEBI.

Key Dates to Watch

• The date for the board meeting to approve the FY26 audited financial results.
• The official announcement of these results.
• Progress on the company's appeal at the Securities Appellate Tribunal (SAT).